These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 7821332)

  • 1. Levodopa and dopamine agonists in the treatment of Parkinson's disease: advantages and disadvantages.
    Ogawa N
    Eur Neurol; 1994; 34 Suppl 3():20-8. PubMed ID: 7821332
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bromocriptine protects mice against 6-hydroxydopamine and scavenges hydroxyl free radicals in vitro.
    Ogawa N; Tanaka K; Asanuma M; Kawai M; Masumizu T; Kohno M; Mori A
    Brain Res; 1994 Sep; 657(1-2):207-13. PubMed ID: 7820619
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Short review on dopamine agonists: insight into clinical and research studies relevant to Parkinson's disease.
    Radad K; Gille G; Rausch WD
    Pharmacol Rep; 2005; 57(6):701-12. PubMed ID: 16382188
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pergolide : A Review of its Pharmacology and Therapeutic Use in Parkinson's Disease.
    Markham A; Benfield P
    CNS Drugs; 1997 Apr; 7(4):328-40. PubMed ID: 27520755
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dopamine D2 receptor-mediated antioxidant and neuroprotective effects of ropinirole, a dopamine agonist.
    Iida M; Miyazaki I; Tanaka K; Kabuto H; Iwata-Ichikawa E; Ogawa N
    Brain Res; 1999 Aug; 838(1-2):51-9. PubMed ID: 10446316
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dopaminergic functional supersensitivity: effects of chronic L-dopa and carbidopa treatment in an animal model of Parkinson's disease.
    Hossain MA; Weiner N
    J Pharmacol Exp Ther; 1993 Dec; 267(3):1105-11. PubMed ID: 8263772
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pramipexole has ameliorating effects on levodopa-induced abnormal dopamine turnover in parkinsonian striatum and quenching effects on dopamine-semiquinone generated in vitro.
    Asanuma M; Miyazaki I; Diaz-Corrales FJ; Shimizu M; Tanaka K; Ogawa N
    Neurol Res; 2005 Jul; 27(5):533-9. PubMed ID: 15978181
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dopamine agonist cabergoline inhibits levodopa-induced caspase activation in 6-OHDA-lesioned mice.
    Tanaka K; Ogawa N
    Neurosci Res; 2005 Jan; 51(1):9-13. PubMed ID: 15596235
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Initial therapy for Parkinson's disease: levodopa vs. dopamine receptor agonists.
    Kondo T
    J Neurol; 2002 Sep; 249 Suppl 2():II25-9. PubMed ID: 12375060
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Does treatment with dopamine agonists affect utilization of exogenous levodopa in the parkinsonian striatum?
    Melamed E
    J Neural Transm Suppl; 1995; 45():57-60. PubMed ID: 8748609
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of the putative dopamine D1 agonist and D2 antagonist FCE 23884 on Parkinson's disease.
    Metman LV; Blanchet PJ; de Jong D; Mouradian MM; Chase TN
    Mov Disord; 1996 May; 11(3):257-60. PubMed ID: 8723141
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of Parkinson's disease: problems with a progressing disease.
    Rinne UK
    J Neural Transm; 1981; 51(1-2):161-74. PubMed ID: 7264627
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacodynamic and pharmacokinetic features of cabergoline. Rationale for use in Parkinson's disease.
    Fariello RG
    Drugs; 1998; 55 Suppl 1():10-6. PubMed ID: 9483165
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Downregulation of striatal dopamine D2 receptors in advanced Parkinson's disease contributes to the development of motor fluctuation.
    Hwang WJ; Yao WJ; Wey SP; Shen LH; Ting G
    Eur Neurol; 2002; 47(2):113-7. PubMed ID: 11844900
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of zingerone [4-(4-hydroxy-3-methoxyphenyl)-2-butanone] and eugenol [2-methoxy-4-(2-propenyl)phenol] on the pathological progress in the 6-hydroxydopamine-induced Parkinson's disease mouse model.
    Kabuto H; Yamanushi TT
    Neurochem Res; 2011 Dec; 36(12):2244-9. PubMed ID: 21769642
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Protective effects of pergolide on dopamine levels in the 6-hydroxydopamine-lesioned mouse brain.
    Asanuma M; Ogawa N; Nishibayashi S; Kawai M; Kondo Y; Iwata E
    Arch Int Pharmacodyn Ther; 1995; 329(2):221-30. PubMed ID: 8540762
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Levodopa + carbidopa + entacapone. Entacapone: a second look: new preparations. Parkinson's disease: a modest effect.
    Prescrire Int; 2005 Apr; 14(76):51-4. PubMed ID: 15875340
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dopaminergic substitution in Parkinson's disease.
    Müller T
    Expert Opin Pharmacother; 2002 Oct; 3(10):1393-403. PubMed ID: 12387685
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bromocriptine in Parkinson disease.
    Lieberman AN; Goldstein M
    Pharmacol Rev; 1985 Jun; 37(2):217-27. PubMed ID: 3901046
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dopaminergic drugs in development for Parkinson's disease.
    Korczyn AD
    Adv Neurol; 2003; 91():267-71. PubMed ID: 12442685
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.